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Abstract
Background: In the context of tumor immunology, tumor cells have been shown to overexpress CD47, an anti-
phagocytic signal directed to macrophages to escape from phagocytosis by interacting with Signal Regulatory
Protein α SIRPα.
In the present work, we designed Polypurine reverse Hoogsteen hairpins, PPRHs, to silence the expression of CD47
in tumor cells and SIRPα in macrophages with the aim to eliminate tumor cells by macrophages in co-culture
experiments.
Methods: THP-1 cells were differentiated to macrophages with PMA. The mRNA levels of differentiation markers
CD14 and Mcl-1 mRNA and pro-inflammatory cytokines (IL-1β, IL-18, IL-6, IL-8 and TNF-α) were measured by qRT-
PCR. The ability of PPRHs to silence CD47 and SIRPα was evaluated at the mRNA level by qRT-PCR and at the
protein level by Western Blot. Macrophages were co-cultured with tumor cells in the presence of PPRHs to silence
CD47 and/or SIRPα. Cell viability was assessed by MTT assays.
Results: THP-1 cells differentiated to macrophages with PMA showed an increase in macrophage surface markers
(CD14, Mcl-1) and pro-inflammatory cytokines (IL-1β, IL-18, IL-6, IL-8 and TNF-α). PPRHs were able to decrease both
CD47 expression in MCF-7 cell line and SIRPα expression in macrophages at the mRNA and protein levels. In the
presence of PPRHs, MCF-7 cells were eliminated by macrophages in co-culture experiments, whereas they survived
in the absence of PPRHs.
Conclusions: Our data support the usage of PPRHs to diminish CD47/SIRPα interaction by decreasing the
expression of both molecules thus resulting in an enhanced killing of MCF-7 cells by macrophages, which might
translate into beneficial effects in cancer therapy. These results indicate that PPRHs could represent a new approach
with immunotherapeutic applications.
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Background
The identification and elimination of tumor cells by the
immune system on the basis of expression of tumor-
specific antigens is the general concept of tumor im-
mune surveillance which was first discussed over a
century ago [1]. The critical components of the immune
system involved in tumor elimination are macrophages.
Macrophage cytotoxicity in tumors can be mediated
by cytokines such as tumor necrosis factor (TNF), by
direct phagocytosis or combination of both [2], although
primary elimination of tumor cells by macrophages oc-
curs via phagocytosis [3]. The mechanism of tumor
elimination by macrophage phagocytosis relies on distin-
guishing non-self molecules from self-molecules. There
are several mechanisms to prevent macrophages from
reacting to own tissues and there are also several mecha-
nisms to trigger phagocytosis against tumor cells. These
processes are achieved by many of the molecules and
signaling pathways involved in macrophage recognition.
When the specific identification of tumor cells by mac-
rophages fails, cancer cells can evade elimination by the
immune system, which has been shown as one of the
hallmarks of cancer [4].
Recently, phagocytosis has been described as the result
of balance between pro-phagocytic and anti-phagocytic
ligands. In the last 10 years, studies have identified the
large variety of pro-phagocytic molecules expressed by
human tumors to induce phagocytosis and allow the im-
mune system to eradicate them. However, a recent and
promising anti-phagocytic molecule is CD47, which
serves as a signal to avoid the macrophage phagocytosis
when interacting its receptor Signal Regulatory Protein
α (SIRPα) on macrophages [5–7].
CD47 or integrin associated protein, is an ubiquitously
expressed cell surface protein in the immunoglobulin
superfamily that binds many different proteins includ-
ing integrins and thrombospondin-1, and it is associ-
ated with variable physiological processes including cell
migration, neuronal development and T cell activation
[8, 9]. CD47 consists of a highly glycosylated extracellu-
lar immunoglobulin variable (lgV) domain, a hydropho-
bic five transmembrane domain and an intracellular
domain [10].
Poels et al. first identified CD47 as a tumor antigen on
human ovarian cancer in 1986 [11]. Since then, many
different human tumor types such as myeloid leukemia,
non-Hodgkin’s lymphoma, bladder cancer and other
solid tumors have also been found to express CD47 [8].
CD47 is widely expressed on all cell types although
tumor cells have increased levels of CD47 expression
compared to normal cells, which turns into a mechan-
ism by which tumor cells can evade phagocytosis.
CD47 functions as an inhibitor of phagocytosis, since
its interaction with its receptor SIRPα in macrophages
leads tumor cells to be recognized as self-molecules. The
interaction of CD47 with SIRPα results in the phosphor-
ylation of immune receptor tyrosine-based inhibition
motifs on SIRPα cytoplasmic tail and leads to the accu-
mulation of myosin-IIA at the phagocytic synapse by the
recruitment of Src homology phosphatase-1 and 2,
which inhibit phagocytosis function [12]. Cells that dis-
play lower levels of CD47 are primed for removal,
whereas cells expressing elevated levels of CD47 are
resistant to clearance.
Given the importance of SIRPα-CD47 interaction for
tumor growth, CD47 has been used as a validated target
for cancer therapies [8]. In this study, we used Polypur-
ine reverse Hoogsteen hairpins (PPRHs) as a gene silen-
cing tool to decrease CD47 in tumor cells and SIRPα in
PMA-differentiated THP-1 cells with the aim to de-
crease their interaction and to eliminate tumor cells.
PPRHs are non-modified DNA molecules formed by
two antiparallel polypurine stretches. These stretches are
linked by a 5-thymidine loop and the intramolecular
linkage consists of reverse Hoogsteen bonds between
adenine and guanine of two antiparallel stretches. When
PPRHs bind their polypyrimidine target sequence by
Watson-Crick bonds, they form a triplex structure,
which results in the displacement of the fourth strand of
the dsDNA [13, 14]. Two types of PPRHs have been de-
scribed depending on the location of their target in tem-
plate or coding DNA strands [15]. PPRHs bound to the
template DNA strand interfere and inhibit transcription,
thus decrease the mRNA and protein levels of the target
gene, whereas PPRHs against the coding DNA strand
are able to bind both to the coding strand of DNA and
to the mRNA, since they have the same sequence and
orientation [15]. PPRHs, despite performing a similar
function than siRNA, do not activate the innate inflam-
matory response and they have demonstrated a longer
half-life in mouse, human and fetal calf serum as well as
in in vitro cell lines compared to siRNAs [16].
Due to the lack of purity and the limited availability of
primary tissue macrophages, the THP-1 cell line is com-
monly used as a model of macrophages, since it resembles
primary monocytes in morphology and differentiation
properties [17–20]. To differentiate monocytic cell lines to
macrophages, THP-1 cells are treated with PMA, which is
a well-studied differentiation-inducing chemical and acts
as an analog of diacyl glycerol [21]. PMA activates protein
kinase C, and triggers serine/threonine kinases involved in
the regulation of cellular proliferation, survival and differ-
entiation [22, 23].
The aims of this study were: to decrease the levels of
CD47 in tumor cells and SIRPα level in PMA-
differentiated THP-1 cells with PPRHs and ultimately to
eliminate tumor cells by macrophages by diminishing
the CD47/SIRPα interaction in co-culture experiments.
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Methods
Cell culture and PMA induced differentiation
Human acute monocytic leukemia THP-1, breast adeno-
carcinoma MCF-7 cell lines were used throughout the
experiments.
Cell lines were grown in Ham’s F-12 medium supple-
mented with 7 % fetal bovine serum (FBS, both from
GIBCO, Invitrogen) at 37 °C in a humidified 5 % CO2
atmosphere. Trypsinization of MCF-7 cells was per-
formed using 0,05 % Trypsin in PBS 1× (154 mM NaCl,
3,88 mM H2NaPO4, 6,1 mM HNaPO4, pH 7,4). Subcul-
ture of THP-1 was performed without trypsinization de-
pending on cell density. For differentiation, THP-1 cells
were plated in 6-well dishes and induced to differentiate
into macrophages using 1–3 ng/ml (~5 nM) phorbol 12-
myristate 13-acetate (PMA) dissolved in dimetyl sulfox-
ide (DMSO). After PMA induction, THP-1 cells changed
morphology and adhered to the culture dish. To deter-
mine macrophage differentiation, non-adherent cells
were removed and mRNA levels of pro-inflammatory cy-
tokines (IL-1β, IL-18, IL-6, IL-8 and TNF-α) and macro-
phage surface markers (CD14 and Mcl-1) were
measured by qRT-PCR at various time points.
Design of PPRHs
PPRHs were designed using the Triplex-Forming Oligo-
nucleotide Target Sequence Search software (spi.mdander-
son.org/tfo/, M.D. Anderson Cancer Center, Houston,
TX). This software searches for polypurine sequences for
the gene of interest. The output gives the location of the
sequence within the gene, either the forward or the re-
verse strand, its exact starting point in the gene sequence
and its location in the promoter, exon or intron. Only se-
quences with a minimum length of 20 nucleotides have
been selected. After selecting proper candidates, BLAST
analyses were preformed to confirm specificity of se-
quences and to avoid unintended targets. PPRHs were
synthesized as non-modified, desalted oligodeoxynucleo-
tides by Sigma-Aldrich (0.05 μmol scale). PPRHs were dis-
solved in sterile Tris-EDTA buffer (1 mM EDTA and
10 mM Tris, pH 8.0) and stored at −20 °C.
As negative controls scrambled sequences were used.
Those PPRHs (Hp-Sc) do not bind to the target and
have similar content in guanines than the specific
PPRHs used. The sequences of the PPRHs used in this
study and their abbreviations are described in Table 1.
Transfection of PPRHs
Cells were plated in 6-well dishes. 100 nM PPRHs lipo-
fected with 10 μM N-[1- (2,3-dioleoyloxy)propyl]-N,
N,N-trimethylammonium methylsulfate (DOTAP; Bion-
tex) in a volume of 200 μl of medium was incubated for
20 min at room temperature before addition of the mix-
ture to the cells in a final volume of 1 ml.
Anti-CD47 treatment
Cells were plated in 6-well dishes. 10 μg/mL of CD47
anti-rabbit antibody (1:20 dilution; sc-25773; Santa Cruz
Biotechnology) was added to the cells in a final volume
of 1 mL.
Co-culture experiments
MCF-7 (60,000) and THP-1 cells (1000) were plated in
6-well dishes separately and THP-1 cells were immedi-
ately transfected with PPRHs against SIRPα and the
negative control, as explained in the corresponding sec-
tion. After 24 h, transfected THP-1 cells were added to
MCF-7 cells and treated with 3 ng/ml PMA for differen-
tiation (Fig. 1). Three days after PMA treatment, the
PMA-containing medium was aspirated and PPRHs
against CD47 and the negative control were transfected
Table 1 PPRHs designed against the CD47 and SIRPα gene, as
well as the scrambled PPRH













-Location within the gene sequence: Pr for promoter; I for intron and number
indicates which intron
- Type of PPRH: −T for Template-PPRHs, −C for Coding-PPRHs and –Sc for
scrambled PPRHs
- Letters in bold indicate polypirimidine interruptions in the sequence
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in fresh F12 medium. At the same time, antibody against
CD47 was added as positive control. Cell viability was
assessed 5 days after transfection by MTT assays.
MTT assays
Cells were plated in 6-well dishes in F12 medium in a
total volume of 1 ml. Five days after transfection,
0.63 mM of 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyl-
tetrazolium bromide and 100 μM of sodium succinate
(both from Sigma-Aldrich, Madrid, Spain) were added to
the culture medium and incubated for 2.5 h at 37 °C for
the reaction. After incubation, the medium was removed
and the solubilization reagent (0.57 % acetic acid and
10 % sodium dodecyl sulfate in DMSO) (Sigma-Aldrich)
was added. Cell viability was measured at 570 nm in a
WPA S2100 Diode Array spectrophotometer. The re-
sults were expressed as the percentage of cell survival
relative to the controls.
Apoptosis assay
Apoptosis was determined by the rhodamine method:
48 h after the transfection against CD47, rhodamine
(final concentration 5 μg/mL) (Sigma-Aldrich) was
added for 30 min, the cells were collected, centrifuged at
800 g at 4 °C for 5 min, and washed once in PBS. The
pellet was resuspended in 500 mL of PBS with PI (final
concentration 5 μg/mL; (Sigma-Aldrich). Flow cytometry
analyses were performed in a CyAn™ ADP (Beckman
Coulter, Inc.) and data were analyzed using the software
Summit v4.3. The percentage of Rho-negative and IP-
negative cells corresponded to the apoptotic population.
RNA extraction
Total RNA was extracted from cells using TRIzol® (Life
Technologies) following the manufacturer’s specifica-
tions. RNA was quantified by measuring its absorbance
at 260 nm using a NanoDrop ND-1000 spectrophotom-
eter (Thermo Scientific).
Reverse transcription
cDNA was synthesized by reverse transcription in a
20 μl reaction mixture containing 500 ng of total
RNA, 125 ng/μl of random hexamers (Roche), 20
units of RNAse inhibitor (Lucigen), 500 μM of each
dNTP (AppliChem), 2 μL of 10× buffer, and 200 units
of Moloney murine leukemia virus reverse transcript-
ase (Lucigen). The reaction was incubated at 42 °C
for 1 h.
Real-time PCR
mRNA levels were determined by SYBR-Green Real-
Time PCR in a final volume of 20 μl, containing 1×
SYBR® Select Master Mix (Life Technologies), 0.25 μM
of reverse and forward primers (Sigma-Aldrich), 2 or
3 μl of cDNA and H2O mQ up to 20 μl. PCR cycling
conditions were 10 min denaturation at 95 °C, 40 cycles
Fig. 1 Schematic representation of co-culture experiments. MCF-7 and THP-1 cells were plated in separate dishes and THP-1 cells were immediately
transfected with PPRHs against SIRPα. After 24 h, transfected THP-1 cells were added to MCF-7 cells and differentiated to macrophages with PMA for
3 days. After that period of time, the medium was replaced with fresh F12 medium and PPRHs against CD47 were transfected. Cell viability (MTT) assay
was assessed 5 days after the last transfection
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of 15 s at 95 °C and 1 min at 60 °C, followed by dissoci-
ation stage for 15 s at 95 °C, 20 s at 60 °C and 15 s at
95 °C.
Fold changes in gene expression were calculated using
the comparative CT (ΔΔCT) method, where CT is the
threshold cycle number at which fluorescence of ampli-
fied mRNA passes the threshold. GAPDH levels were
used as endogenous controls. All the primers used in
these experiments are detailed in Table 2.
Western blot analyses
Cells were plated in 6-well dishes and treated with 100
nM PPRHs as described in Transfection of PPRHs sec-
tion. For MCF-7 cells, 3 h after transfection, total pro-
tein extracts were obtained with deoxycholate buffer
(100 mM NaCl, 10 mM NaH2PO4 pH 7.4, 1 μM PMSF,
1 % triton, 0.1 % SDS and 0.5 % deoxycholic acid). Cells
were washed with PBS 1× and collected by scraper in
100 μL of deoxycholate buffer. Cell debris was removed
by centrifugation (13,500 × g at 4 °C for 10 min).
For THP-1 cells, cells were collected 24 h after trans-
fection and centrifuged for 5 min at 800 g at 4 °C. Cells
were resuspended in 50 μl of RIPA buffer (150 mM
NaCl, 5 mM EDTA, 50 mM Tris–HCl pH 7.4 (all from
Applichem, Barcelona, Spain), 1 % Igepal CA-630,
100 μg/ml PMSF and Protease inhibitor cocktail (all
from Sigma-Aldrich). Cell lysate was kept on ice for
30 min, vortexing every 10 min. Cell debris was
removed by centrifugation at 13,500 g at 4 °C for
10 min. The Bradford method was used to determine
protein concentration using bovine serum albumin as a
standard.
Whole cell extracts were resolved in 10 % SDS-
polyacrylamide gels and transferred to PVDF membranes.
The blocking solution was 5 % Blotto. Membranes were
probed overnight at 4 °C with primary antibodies against
CD47 (1:50 dilution; sc-25773, Santa Cruz Biotechnology,
Heidelberg, Germany), SIRPα (1:50 dilution; sc-373896,
Santa Cruz Biotechnology, Heidelberg, Germany) or
GAPDH (1:100 dilution; MAB374; Chemicon Inter-
national, USA). Signals were detected by secondary HRP-
conjugated antibodies: anti-rabbit (1:1000 dilution; Dako,
Denmark) for CD47 and anti-mouse (1:1000 dilution; sc-
2005, Santa Cruz Biotechnology, Heidelberg, Germany)
for GAPDH and SIRPα. Chemiluminescence was detected
with ImageQuant LAS 4000 mini technology (GE
Healthcare).
Statistical analyses
All data was recorded as mean ± standard error of the
mean (SE). Analyses were performed using Student’s t
test with the software IBM SPSS Statistics v20. Signifi-
cance was defined as p < 0.05.
Results
Expression of surface markers in PMA-treated THP-1 cells
PMA treatment of THP-1 monocytes has been com-
monly used to study macrophages in vitro and different
differentiation protocols including variable concentra-
tion of PMA for different time periods have been re-
ported so far [18]. We analyzed the effect of either 1 or
3 ng/ml PMA in THP-1 cells for 48 h, 72 h or 72 h +
rest (72 h followed by 48 h resting in fresh medium).
Cell morphology after PMA treatment was examined
under the microscope for all conditions. Cell adhesion
and spreading, which are hallmarks of macrophages,
were observed at all indicated time points with both 1
and 3 ng/ml PMA. CD14 [19, 20, 23–25] and Mcl-1 [26]
up-regulation have been reported to be differentiation
markers of macrophages upon incubation of THP-1 cells
with PMA. Therefore, to determine the concentration
and incubation time of PMA required to differentiate
THP-1 monocytes to macrophages, mRNA levels of
CD14 and Mcl-1 were determined by qRT-PCR (Fig. 2).
CD14 expression was highly enhanced using 3 ng/ml
PMA for 72 h + rest (Fig. 2a) and Mcl-1 expression was
increased at 48 h and its elevated level maintained at
72 h + rest for both concentrations of PMA (Fig. 2b).
Table 2 Sequences of the primers used in the qRT-PCR and the amplified product sizes
Target gene Forward sequence (5′-3′) Reverse sequence (5′-3′) Product size (bp)
GAPDH CCATGTTCGTCATGGGTGTGAACCA GCCAGTAGAGGCAGGGATGATGTTC 251
CD14 GCAGCCGAAGAGTTCACAAG CGCGCTCCATGGTCGATAAG 129
CD47 GAGTCTCTGTATTGCGGCGTG GGGGTTCCTCTACAGCTTTCC 161
IL-1β GTGGCAATGAGGATGACTTGTTC TAGTGGTGGTCGGAGATTCGTA 124
IL-18 CCTCAGACCTTCCAGATCGC TTCCAGGTTTTCATCATCTTCAGC 159
IL-6 CATTTGTGGTTGGGTCAGG AGTGAGGAACAAGCCAGAGC 112
IL-8 CCACCGGAAGGAACCATCTC TTCCTTGGGGTCCAGACAGA 279
Mcl-1 GACGAGTTGTACCGGCAGTCG TTGATGTCCAGTTTCCGAAGC 200
SIRPα AAATACCGCCGCTGAGAACA TGTCCTGTGTTATTTCTCTGGCA 197
TNF-α GCCAGAGGGCTGATTAGAG TCAGCCTCTTCTCCTTCCTG 124
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PMA induced pro-inflammatory cytokines expression in a
dose and time dependent manner
Increased expression of cytokines is one of the
phenotypic characteristics of differentiated macro-
phages [19, 20, 27]. To further investigate if THP-1
cells were able to differentiate to macrophages at 1
and 3 ng/ml PMA, mRNA expression of 5 different
pro-inflammatory cytokines (IL-1β, IL-18, IL-6, IL-8,
and TNF-α) was analyzed by qRT-PCR (Fig. 3). After
the addition of PMA, levels of pro-inflammatory cyto-
kines were increased dose and time dependently rela-
tive to untreated THP-1 cells. It is worth noting that
the levels of cytokines produced in response to PMA
are not the same depending on the culture conditions
[18]. IL-1β was elevated in all conditions whereas 3 ng/ml
PMA induced the highest expression when treated for
72 h (Fig. 3a). IL-18 (Fig. 3b), IL-6 (Fig. 3c) and IL-8
(Fig. 3d) stimulated at the highest level with 3 ng/ml PMA
for 72 h + rest and TNF-α (Fig. 3e) increased 4.4 fold with
3 ng/ml PMA for 72 h. These results suggested that THP-
1 cells could be differentiated to macrophages using
3 ng/ml PMA for 72 h and the levels of pro-inflammatory
cytokines remained enhanced for the 72 h treatment
followed by 48 h resting, which was also reflected in the
up-regulated surface markers levels.
Effects of PPRHs on CD47 and SIRPα levels
Two types of PPRHs against CD47 were used in the
experiments, targeting either the promoter (HpCD47Pr-
T) or intron 1 (HpCD47I3-T) in the template strand of
the DNA (Table 1). To explore the ability of PPRHs to
silence CD47, CD47 mRNA levels were analyzed in
MCF-7 cells either in the absence or in the presence of
PPRHs. Both HpCD47I3-T and HpCD47Pr-T were able
to decrease CD47 mRNA levels down to 2-fold in MCF-
7 cells compared to the control (Fig. 4a). To target
SIRPα, HpSIRPαPr-C, designed against the promoter
sequence and HpSIRPαI7-T, designed against the intron
7 sequence (Table 1) were transfected in THP-1 cells. A
decrease in SIRPα expression was achieved with both
Fig. 2 mRNA levels of macrophage surface markers. THP-1 cells (100,000) were treated with either 1 or 3 ng/ml PMA for 48 h, 72 h or 72 h + rest
(72 h PMA incubation followed by 48 h resting in fresh medium). Expression of surface markers CD14 (a) and Mcl-1 (b) was determined
by qRT-PCR and the results expressed relative to untreated THP-1 cells. Data represent the mean ± SE of at least three experiments
(*p < 0.05, **p < 0.01, ***p < 0.005)
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PPRHs (Fig. 4b). The effects of PPRHs on CD47 and
SIRPα were also determined at the protein level in
MCF-7 and THP-1 cells, respectively (Fig. 4c,d). Both
PPRHs targeting CD47 decreased the protein level by
2.5 fold (Fig. 4c). Likewise, SIRPα protein levels were
reduced by both HpSIRPαPr-C and HpSIRPαI7-T
(Fig. 4d).
Effect of PPRHs in MCF-7 cells and in Co-culture
experiments
Before proceeding to co-culture experiments, we deter-
mined the cytotoxicity of the different PPRHs against
either CD47 or SIRPα in MCF-7 cells. Thus, we trans-
fected the 4 PPRHs at the same concentration of 100
nM. Whereas HpCD47I3-T and HpSIRPαPr-C caused a
cytotoxicity of 48 and 28 %, respectively, HpCD47Pr-T
and HpSIRPαI7-T only caused a cytotoxicity of 8 and
18 %, respectively. Given that the last two PPRHs were
practically not cytotoxic in MCF-7 cells, they were se-
lected for the co-culture experiments. The rationale for
this was that we wanted to analyze the cytotoxic effect
of macrophages on MCF-7 cells that had reduced CD47
levels by PPRHs, which were not cytotoxic by them-
selves. Also, because it was important for the co-culture
experiment, we determined the lack of CD47 expression
in THP-1 cells relative to MCF-7 and of SIRPα expres-
sion in MCF-7 relative to THP-1 cells (data not shown).
Based on the patterns of pro-inflammatory cytokines
and surface markers levels, 3 ng/ml of PMA was chosen
for THP-1 differentiation. To decrease CD47/SIRPα
interaction, CD47 and SIRPα alone or in combination
were targeted by PPRHs. Scrambled PPRHs were used
as negative controls and an antibody anti-CD47 as posi-
tive control to disrupt the interaction CD47/SIRPα
Fig. 3 mRNA levels of pro-inflammatory cytokines. THP-1 cells (100,000) were treated with either 1 or 3 ng/ml PMA for 48 h, 72 h or 72 h + rest
(72 h PMA incubation followed by 48 h resting in fresh medium). Expression of IL-1β (a), IL-18 (b), IL-6 (c), IL-8 (d), and TNF-α (e) was determined
by qRT-PCR and the results expressed relative to untreated THP-1 cells. Data represent the mean ± SE of at least three experiments (*p < 0.05,
**p < 0.01, ***p < 0.005)
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(Fig. 5). By decreasing the level of CD47 in tumor cells,
60 % of MCF-7 cells were killed by macrophages (Fig. 5).
When transfecting THP-1 cells with HpSIRPαI7-T, the
decreased level of SIRPα allowed macrophages to kill
58 % of tumor cells (Fig. 5). To decrease the level of
both targets in the same co-culture and to better kill
tumor cells, THP-1 cells were first transfected with
HpSIRPαI7-T and after differentiation, MCF-7 cells were
transfected with HpCD47Pr-T in the co-culture. In these
conditions, 70 % of tumor cells were eliminated. Similar
results were obtained under anti-CD47 treatment. On
the other hand, tumor cells escaped from macrophage
killing in the absence of PPRHs and the cell viability
when transfected with scrambled PPRHs was reduced by
25 % compared to that of the co-culture control (Fig. 5).
Apoptosis assay
To associate the dead mechanism to the cytotoxic effect
observed in the co-culture, we measured the apoptotic
effect of the PPRHs at 100 nM after 48 h of incubation
using the rhodamine method (Fig. 6). Co-culture trans-
fected with HpCD47Pr-T and HpSIRPαI1-T provoked a
3-fold increase in apoptosis compared to MCF-7 cells
treated with PMA, which was higher than the apoptotic
effect triggered by anti-CD47 antibody (1.7-fold) used as
positive control. No significant difference was detected
in the co-culture control whereas the percentage of
apoptotic cells in the co-culture transfected with
HpCD47-Sc and HpSIRPα-Sc was twice that of the con-
trol MCF-7 cells treated with PMA.
Discussion
In this work, we explored the usage of specific PPRHs to
decrease the expression of CD47 and SIRPα to stimulate
the elimination of tumor cells by macrophages, which
constitutes a new approach in tumor immunotherapy.
So far, it has been shown that different concentrations
and time of exposure to PMA induce THP-1 differenti-
ation resulting in different macrophage phenotypes with
altered expression of a wide range of genes at various
levels. CD14 is a widely used marker to study monocyte-
macrophage differentiation and its up-regulated expres-
sion is associated with macrophage phenotype [19, 20,
23–25]. The anti-apoptotic molecule Mcl-1 has also
Fig. 4 CD47 and SIRPa levels upon PPRHs transfection. a MCF-7 cells (60,000) were plated one day before transfection with PPRHs against CD47.
RNA was extracted 24 h after transfection. mRNA levels were determined by qRT-PCR using untransfected cells as control. b THP-1 cells (15,000)
were plated and transfected with PPRHs against SIRPα. Other conditions were as in A). Data represent the mean ± SE of at least three experiments
(*p < 0.05, **p < 0.01, ***p < 0.005). c MCF-7 cells (60,000) were plated one day prior to transfection of PPRHs against CD47 and total protein was
extracted 3 h after transfection. A representative Western blot image of CD47 protein levels upon PPRHs transfection is shown. d THP-1 cells
(15,000) were plated and transfected with PPRHs against SIRPα and total protein was extracted 24 h after transfection. Control corresponded to
untransfected cells. A representative Western blot image of SIRPα protein levels upon PPRHs transfection is shown
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been identified as a differentiation dependent marker
[22, 25]. High concentrations of PMA were previously
found to induce undesirable gene up-regulation, and
concentrations lower than 10 ng/ml were suggested for
attain stable differentiation [18]. In the present study, we
treated THP-1 cells with either 1 or 3 ng/ml PMA for
incubation times commonly used in the literature (48 to
72 h), to observe the effect of different culture condi-
tions on differentiation. Differentiation of THP-1 cells is
mainly conducted with PMA treatment for 48 h or 72 h
although Daigneault et al. [19] demonstrated that treat-
ing THP-1 cells with PMA followed by a period of fur-
ther culture without PMA differentiates THP-1 cells to
macrophages with a high capability of phagocytosis and
it enhances differentiation [19]. Our data demonstrated
that the highest CD14 level was reached with a PMA
treatment for 72 h followed by 48 h of resting without
PMA. In accordance with previous studies, we demon-
strated that both CD14 and Mcl-1 levels were increased
with PMA treatment in a time and dose dependent
manner.
In addition to surface markers, PMA has also been re-
ported to induce the production of pro-inflammatory cy-
tokines in THP-1 cells [27–29]. IL-1β, IL-18, IL-6, IL-8
and TNF-α are produced by macrophages through the
activation of toll-like receptor signaling, and their pro-
duction is involved in the clearance of tumor cells by
macrophages [30]. Our results showed the induction of
several cytokines in THP-1 cells in response to PMA,
depending on the duration and dose of treatment.
Cancer therapy by stimulating the patient’s immune sys-
tem is one of the most promising areas of cancer research.
In contrast to target the adaptive immune system, therap-
ies have been aimed to stimulate macrophages to attack
cancer. Studies have demonstrated that macrophage
phagocytosis is the major mechanism when treating cancer
using antibody therapies aimed to abolish the interaction
between CD47/SIRPα. The efficiency of macrophage medi-
ated tumor elimination by tumor-binding antibodies has
already approved for cancer therapy [30].
As a new approach in immunotherapy, we used PPRHs,
which have already been proved in gene silencing in vitro
Fig. 5 Co-culture experiments. In the co-culture experiments, either only MCF-7 cells (60,000) were transfected with HpCD47Pr-T, only THP-1 cells
(1000) with HpSIRPαI7-T or both MCF-7 and THP-1 cells were transfected with the corresponding PPRH or scrambled PPRHs in controls. As posi-
tive control an antibody anti-CD47 was used. Then THP-1 cells were differentiated with 3 ng/ml PMA. The percentage of viable cells was calcu-
lated relative to the control of MCF-7 cells incubated with 3 ng/ml PMA. Data represent the mean ± SE of at least three experiments (*p < 0.05,
**p < 0.01, ***p < 0.005)
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and in vivo [31]. PPRHs are more stable and show almost
no immunogenicity, relative to siRNAs [16]. Since we pre-
viously described PPRHs as a gene silencing tool against
different cancer targets in different human cell lines [15,
31–33], in this study we designed four different PPRHs to
decrease the level of both CD47 and SIRPα and we dem-
onstrated that all PPRHs were able to silence their target
at both the mRNA and protein level. We showed that
PMA-differentiated THP-1 cells eliminated tumor cells
after decreasing CD47/SIRPα interaction whereas tumor
cells remained unaffected in the absence of PPRHs. We
also demonstrated that the mechanism responsible for ob-
served cell death was apoptosis.
Elevated CD47 expression limits the killing of tumor
cells through its interaction with SIRPα, whereas loss of
CD47 triggers phagocytosis. So far, monoclonal anti-
bodies directed against CD47 have been used to inhibit
this interaction. Anti-CD47 antibodies have shown the
preclinical activity in different cancers both in vitro and
in animal models [6, 9, 34]. In addition to antibodies,
targeting tumor CD47 using antisense strategies is an-
other promising approach to inhibit CD47 function.
Antisense morpholino oligonucleotides have been used
to prevent translation of CD47 mRNA and to suppress
CD47 expression in mice and miniature pigs [35, 36].
Also, antisense and siRNA strategies have been suggested
to offer advantages over CD47 antibodies by avoiding
many of the side effects of therapeutic CD47-antibodies
such as altered blood pressure [37], hemolytic anemia and
pro-thrombotic or anti-thrombotic activities [38].
Recently, Chao et al. have reported the synergic effect
of antibodies against CD47 with the therapeutic cancer
antibody rituximab on the phagocytosis of non-Hodgkin
lymphoma by macrophages in immune-deficient mice
[39]. However, it was believed that this study did not
provide conclusive evidence for the role of CD47/SIRPα
interaction. Furthermore, it has been shown that CD47/
SIRPα and SIRPα signaling negatively regulate antibody-
dependent elimination of tumor cells, which supports
the idea of targeting CD47/SIRPα interaction to enhance
the clinical effects of cancer therapeutic antibodies [40].
SIRPα acts to inhibit in vivo clearance of CD47-
expressing host cells, including red blood cells and plate-
lets, by macrophages [41, 42]. Therefore, direct targeting
of SIRPα in immune cells, rather than CD47 in tumor
cells, could be considered as an alternative approach to
Fig. 6 Apoptosis assay. Effect of PPRHs on apoptosis. In the co-culture experiments, either only MCF-7 cells (60,000) were transfected with
HpCD47Pr-T, only THP-1 cells (1000) with HpSIRPαI7-T or both MCF-7 and THP-1 cells were transfected with the corresponding PPRH or scrambled
PPRHs in controls. As positive control an antibody anti-CD47 was used. Then THP-1 cells were differentiated with 3 ng/ml PMA. 48 h after trans-
fection, apoptosis was measured by Rhodamine method: Cells Rho123-negative and IP-negative were considered as apoptotic cells. Data repre-
sent the fold-change in apoptosis relative to MCF-7 cells treated with PMA. *p < 0.05
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disrupt their interaction. A previous study showed that a
novel human SIRPα-Fc fusion protein resulted in the
preferential phagocytosis of acute myeloid leukemia with
the blockade of CD47/SIRPα [43]. Moreover, SIRPα has
been proposed as a better target due to its relatively re-
stricted tissue expression pattern compared to CD47,
which is ubiquitously expressed and binds to multiple
other ligands [40].
Conclusions
Our data support the usage of PPRHs to diminish
CD47/SIRPα interaction by decreasing the expression of
both molecules thus resulting in an enhanced killing of
tumor cells by macrophages, which might translate into
beneficial effects in cancer therapy. We believe that our
results encourage the use of PPRH technology as an al-
ternative strategy, as a new and promising immunother-
apeutic approach to enhance cancer therapies.
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